25-04-2025
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS25 April 2025 at 17.20 EEST
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 24 April 2025 above five (5) per cent of Orion Corporation's total shares.
Total positions of BlackRock, Inc. and its funds subject to notification:% of shares and voting rights (total of point A)
% of shares and voting rights through financial instruments (total of point B)
Total of both in % (points A + B)
Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached
5.01% shares Below 5% voting rights
0.00% shares Below 5% voting rights
5.01% shares Below 5% voting rights
141,134,278 shares 763,427,275 voting rights
Position of previous notification (if applicable)
Below 5% shares Below 5% voting rights
Below 5% shares Below 5% voting rights
Below 5% shares Below 5% voting rightsNotified details of the resulting situation on the date on which the threshold was crossed:
Point A: Shares and voting rights:
Class/type of sharesISIN code
Number of shares and voting rights
% of shares and voting rightsDirect (SMA 9:5)
Indirect (SMA 9:6 and 9:7)
Direct (SMA 9:5)
Indirect (SMA 9:6 and 9:7)
FI00090143777,071,241 shares Below 5% voting rights5.01% shares Below 5% voting rights
POINT A SUBTOTAL
7,071,241 shares Below 5% voting rights
5.01% shares Below 5% voting rights
Point B: Financial instruments according to SMA 9:6a:
Type of financial instrument
Expiration date
Exercise / Conversion Period
Physical or cash settlement
Number of shares and voting rights
% of shares and voting rights
American Depositary Receipt (US68628Y1047)
N/A
N/A
Physical
145 shares Below 5% voting rights
0.00% shares Below 5% voting rightsPOINT B SUBTOTAL
145 shares Below 5% voting rights
0.00% shares Below 5% voting rights
Orion Corporation
Liisa Hurme President and CEO
Olli Huotari EVP, Corporate Functions Contact person:Tuukka Hirvonen, Investor Relations, Orion Corporationtel. +358 10 426 2721
Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo,
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2024 amounted to EUR 1,542 million and the company had about 3,700 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
